Schrodinger, Inc. Stock Price, News & Analysis

Schrödinger (Nasdaq: SDGR) has granted restricted stock units (RSUs) to four newly hired employees on September 14, 2025. The inducement grants total 1,666 shares of common stock and were issued under the company's 2021 Inducement Equity Incentive Plan.

The RSUs feature a four-year vesting schedule, with 25% vesting after 12 months of continuous service, followed by equal yearly installments of 25% over the subsequent three years. These grants were approved by the compensation committee and comply with Nasdaq Listing Rule 5635(c)(4).

Schrödinger (Nasdaq: SDGR) announced its upcoming participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company's management will engage in a fireside chat scheduled for Monday, September 8, 2025, at 11:30 a.m. E.T. Investors can access the live webcast through the "Investors" section of Schrödinger's website, where it will remain available for approximately 90 days after the event.

Schrödinger (Nasdaq: SDGR) announced the granting of inducement equity awards to two new employees on August 15, 2025. The company awarded a total of 1,875 restricted stock units (RSUs) under its 2021 Inducement Equity Incentive Plan.

The RSUs feature a four-year vesting schedule, with 25% vesting after the first year of continuous service and the remaining 75% vesting in equal yearly installments over the following three years. These grants were approved by the compensation committee and comply with Nasdaq Listing Rule 5635(c)(4).

Schrödinger (Nasdaq: SDGR) announced the discontinuation of its SGR-2921 clinical development program, a CDC7 inhibitor being evaluated in a Phase 1 dose-escalation study for acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes.

The decision comes after two treatment-related deaths in AML patients during the Phase 1 study, despite early evidence of monotherapy activity. The company determined that pursuing development as a combination therapy would be challenging, despite preclinical data showing promising anti-leukemic responses in patient-derived AML models.

Schrödinger (Nasdaq: SDGR) reported Q2 2025 financial results with total revenue of $54.8 million, up 16% year-over-year. Software revenue increased 15% to $40.5 million, while drug discovery revenue reached $14.2 million.

The company presented encouraging Phase 1 data for its MALT1 inhibitor SGR-1505 in B-cell malignancies and received FDA Fast Track Designation for Waldenström macroglobulinemia treatment. Initial clinical data for two other programs, SGR-3515 and SGR-2921, is expected in Q4 2025.

Schrödinger maintained its 2025 software revenue growth guidance of 10-15% and implemented cost-reduction measures, including a 7% workforce reduction expected to save approximately $30 million annually.

Schrödinger (Nasdaq: SDGR) has scheduled its second quarter 2025 financial results announcement for Wednesday, August 6, 2025, after market close. The company will hold a conference call and webcast at 4:30 p.m. ET to discuss the results. Investors can access the live webcast through the "Investors" section of Schrödinger's website, where it will remain available for approximately 90 days.

Schrödinger (Nasdaq: SDGR) announced the granting of restricted stock units (RSUs) to three new employees as part of their employment compensation packages. The grants, totaling 3,488 shares of common stock, were issued on July 14, 2025, under the company's 2021 Inducement Equity Incentive Plan.

The RSUs feature a four-year vesting schedule, with 25% vesting after the first year of continuous service and the remaining 75% vesting in equal yearly installments over the following three years. These grants were approved by the compensation committee and comply with Nasdaq Listing Rule 5635(c)(4).

Schrödinger (NASDAQ:SDGR) and Ajax Therapeutics have expanded their exclusive research collaboration to include a new JAK target, building on their successful partnership established in 2019. The collaboration's lead candidate, AJ1-11095, a potential first-in-class Type II JAK2 inhibitor, is currently in Phase 1 clinical trials for myelofibrosis treatment.

The expanded partnership aims to develop novel JAK inhibitors for both oncology and inflammatory/autoimmune disorders. Under the amended agreement, Ajax will lead clinical development and commercialization, while Schrödinger will receive milestone payments, single-digit royalties on net sales, and maintains its equity stake in Ajax following their participation in Ajax's $95 million Series C financing in 2024.

Schrödinger (Nasdaq: SDGR) announced that its clinical stage MALT1 inhibitor, SGR-1505, has received Fast Track designation from the FDA for treating adult patients with Waldenström macroglobulinemia who have failed at least two lines of therapy, including a BTK inhibitor.

The drug is currently in Phase 1 clinical trials for relapsed/refractory B-cell malignancies, showing encouraging preliminary efficacy and a favorable safety profile. Initial data was presented at recent medical conferences, demonstrating positive results in multiple B-cell malignancy subtypes. The FDA previously granted orphan drug designation to SGR-1505 for Mantle Cell Lymphoma in August 2023.